Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

52.95 UNCHANGED

Last Price Updated: 4:15 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Topics Regulatory Compliance Stocks

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Why Terns Pharmaceuticals Stock Rocked the Market in March ↗

April 08, 2026

A large peer is snapping up the company in a premium-priced deal.

Via The Motley Fool

Topics Intellectual Property

VKTX, TERN, GPCR Shares Rally As Novo Nordisk Sounds Willingness Towards Portfolio-Expansion Deals ↗

January 14, 2026

Via Stocktwits

ARM Makes Its Move While Wall Street Watches the Strait ↗

March 26, 2026

Via Chartmill

The Strategic Renaissance: Why 2026 is the Year of the Takeover Tailwind

March 25, 2026

As of March 25, 2026, the global financial markets are witnessing a seismic shift in corporate strategy, marking the definitive end of the "deal winter" that chilled boardrooms for much of the early...

Via MarketMinute

Topics Artificial Intelligence Economy

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors? ↗

March 23, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a pipeline of proprietary small-molecule drug candidates.

Via The Motley Fool

This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain ↗

March 18, 2026

Axsome Therapeutics develops therapies for central nervous system disorders, with a late-stage pipeline targeting major unmet medical needs.

Via The Motley Fool

Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? ↗

March 18, 2026

This clinical-stage biotech develops therapies targeting the root cause of cystic fibrosis, with a pipeline focused on CFTR modulators.

Via The Motley Fool

Topics Regulatory Compliance

This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names ↗

March 18, 2026

This clinical-stage biopharma targets neurological and psychiatric disorders with a pipeline of novel therapeutics advancing through trials.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Fund Sold $8 Million of Terns Stock Last Quarter, but Here's Why It Still Seems Very Bullish ↗

March 18, 2026

This clinical-stage biotech develops therapies for CML, NASH, and obesity.

Via The Motley Fool

Topics Regulatory Compliance

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

Via The Motley Fool

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗

February 20, 2026

Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s...

Via The Motley Fool

Topics Regulatory Compliance

Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗

February 17, 2026

This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates.

Via The Motley Fool

Topics Regulatory Compliance

Stay updated with the stocks that are on the move in today's after-hours session. ↗

January 02, 2026

Via Chartmill

Terns Pharmaceuticals Stock Jumps After New Leukemia Drug Data Show Strong Patient Responses ↗

December 08, 2025

New Phase 1 data showed strong response rates and a favorable safety profile for its experimental leukemia drug TERN-701.

Via Stocktwits

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗

December 03, 2025

One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.

Via The Motley Fool

Topics Regulatory Compliance

Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗

November 17, 2025

Via Benzinga

Henry Schein, Sanmina, Wingstop, Waters And Other Big Stocks Moving Higher On Tuesday ↗

November 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 04, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

November 03, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Kenvue, IDEXX Laboratories, Freshpet And Other Big Stocks Moving Higher On Monday ↗

November 03, 2025

Via Benzinga

Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades ↗

November 03, 2025

Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.

Via Benzinga

Top movers analysis in the middle of the day on 2025-11-03: top gainers and losers in today's session. ↗

November 03, 2025

Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 03, 2025

Via Benzinga

Gapping stocks in Monday's session ↗

November 03, 2025

In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Why Is Terns Pharmaceuticals Stock Trading Lower After Obesity Trial Data? ↗

October 22, 2025

Terns Pharmaceuticals announces 12-week Phase 2 results for oral obesity drug TERN-601, showing up to 4.6% weight loss but reporting cases of drug-induced liver injury.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.